Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65249 | 0.71 | — | — | |
| SCHEMBL28241233 | 0.68 | LMNA (0.41) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL6201177 | 0.68 | LMNA (0.38) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL12921936 | 0.67 | LMNA (0.43) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL13757852 | 0.67 | LMNA (0.40) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL784347 | 0.67 | ADORA1 (0.40) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL6198132 | 0.66 | LMNA (0.36) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL29757073 | 0.63 | ACHE (0.40) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL18977796 | 0.63 | LMNA (0.35) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL28309008 | 0.63 | LMNA (0.37) | LMNASMN1; SMN2ADORA1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | LMNA 1760/4885SMN1; SMN2 3003/4885ADORA1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.